{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:45:28Z","timestamp":1791755128922,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03823-w","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T08:50:29Z","timestamp":1791708629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methotrexate in Still\u2019s Disease: An Updated Perspective on Efficacy and Safety"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-5759","authenticated-orcid":false,"given":"Karima","family":"Daghor-Abbaci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0101-9585","authenticated-orcid":false,"given":"Oya","family":"Koker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,11]]},"reference":[{"issue":"4","key":"3823_CR1","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10067-023-06509-8","volume":"42","author":"K Daghor-Abbaci","year":"2023","unstructured":"Daghor-Abbaci K, Ait Hamadouche N, Makhloufi CD, et al. Proposal of a new diagnostic algorithm for adult-onset Still\u2019s disease. Clin Rheumatol. 2023;42(4):1125\u201335. https:\/\/doi.org\/10.1007\/s10067-023-06509-8.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"3823_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41584-023-01065-6","volume":"20","author":"P Ruscitti","year":"2024","unstructured":"Ruscitti P, Cantarini L, Nigrovic PA, McGonagle D, Giacomelli R. Recent advances and evolving concepts in Still\u2019s disease. Nat Rev Rheumatol. 2024;20(2):116\u201332. https:\/\/doi.org\/10.1038\/s41584-023-01065-6.","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"3823_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.31138\/mjr.290323.dat","volume":"35","author":"A Kontzias","year":"2024","unstructured":"Kontzias A, Petryna O, Nakasato P, Efthimiou P. Diagnosing and treating systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease as part of the Still\u2019s disease continuum. Mediterr J Rheumatol. 2024;35(Suppl 1):45\u201357. https:\/\/doi.org\/10.31138\/mjr.290323.dat.","journal-title":"Mediterr J Rheumatol"},{"issue":"4","key":"3823_CR4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","volume":"51","author":"P Efthimiou","year":"2021","unstructured":"Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset Still\u2019s disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021;51(4):858\u201374. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.06.004.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"3823_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40265-024-01993-x","volume":"84","author":"S Bindoli","year":"2024","unstructured":"Bindoli S, Baggio C, Doria A, Sfriso P. Adult-onset Still\u2019s disease (AOSD): advances in understanding pathophysiology, genetics and emerging treatment options. Drugs. 2024;84(3):257\u201374. https:\/\/doi.org\/10.1007\/s40265-024-01993-x.","journal-title":"Drugs"},{"issue":"12","key":"3823_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40267-018-0572-5","volume":"34","author":"KA Lyseng-Williamson","year":"2018","unstructured":"Lyseng-Williamson KA. Anakinra in Still\u2019s disease: a profile of its use. Drugs Ther Perspect. 2018;34(12):543\u201353. https:\/\/doi.org\/10.1007\/s40267-018-0572-5.","journal-title":"Drugs Ther Perspect"},{"issue":"12","key":"3823_CR7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614\u201327. https:\/\/doi.org\/10.1136\/ard-2024-225851.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3823_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000287","volume":"2","author":"JM Kremer","year":"2016","unstructured":"Kremer JM, Lawrence DA, Hamilton R, McInnes IB. Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open. 2016;2(1):e000287. https:\/\/doi.org\/10.1136\/rmdopen-2016-000287.","journal-title":"RMD Open"},{"key":"3823_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152244","volume":"62","author":"P Ruscitti","year":"2023","unstructured":"Ruscitti P, Sota J, Vitale A, et al. The administration of methotrexate in patients with Still\u2019s disease, \u201creal-life\u201d findings from AIDA Network Still Disease Registry. Semin Arthritis Rheum. 2023;62:152244.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"3823_CR10","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","volume":"39","author":"D Nordstr\u00f6m","year":"2012","unstructured":"Nordstr\u00f6m D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39(10):2008\u201311. https:\/\/doi.org\/10.3899\/jrheum.111549.","journal-title":"J Rheumatol"},{"key":"3823_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaut.2016.02.010","volume":"69","author":"U Kalyoncu","year":"2016","unstructured":"Kalyoncu U, Solmaz D, Emmungil H, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still\u2019s disease: data from a large multicenter cohort. J Autoimmun. 2016;69:59\u201363. https:\/\/doi.org\/10.1016\/j.jaut.2016.02.010.","journal-title":"J Autoimmun"},{"issue":"8","key":"3823_CR12","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/art.27532","volume":"62","author":"S Franchini","year":"2010","unstructured":"Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still\u2019s disease. Arthritis Rheum. 2010;62(8):2530\u20135. https:\/\/doi.org\/10.1002\/art.27532.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3823_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/ard.56.2.144","volume":"56","author":"T Fujii","year":"1997","unstructured":"Fujii T, Akizuki M, Kameda H, et al. Methotrexate treatment in patients with adult onset Still\u2019s disease--retrospective study of 13 Japanese cases. Ann Rheum Dis. 1997;56(2):144\u20138. https:\/\/doi.org\/10.1136\/ard.56.2.144.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3823_CR14","first-page":"373","volume":"26","author":"B Fautrel","year":"1999","unstructured":"Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still\u2019s disease. J Rheumatol. 1999;26(2):373\u20138.","journal-title":"J Rheumatol"},{"issue":"5 Suppl 61","key":"3823_CR15","first-page":"S168","volume":"28","author":"B Manger","year":"2010","unstructured":"Manger B, Rech J, Schett G. Use of methotrexate in adult-onset Still\u2019s disease. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S168-71.","journal-title":"Clin Exp Rheumatol"},{"key":"3823_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fmed.2020.00042","volume":"7","author":"A Vitale","year":"2020","unstructured":"Vitale A, Cavalli G, Ruscitti P, et al. Comparison of early vs. delayed anakinra treatment in patients with adult-onset Still\u2019s disease and its effect on clinical and laboratory outcomes. Front Med (Lausanne). 2020;7:42. https:\/\/doi.org\/10.3389\/fmed.2020.00042.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"3823_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10067-024-06905-8","volume":"43","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Kataoka Y, Otani T, et al. Optimal time of starting tocilizumab in acute phase of adult-onset Still\u2019s disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature. Clin Rheumatol. 2024;43(3):1245\u201351. https:\/\/doi.org\/10.1007\/s10067-024-06905-8.","journal-title":"Clin Rheumatol"},{"issue":"32","key":"3823_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016682","volume":"98","author":"CY Wang","year":"2019","unstructured":"Wang CY, Guo SH, Wang LP, Shen HL. Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: a STROBE-compliant article. Medicine (Baltimore). 2019;98(32):e16682. https:\/\/doi.org\/10.1097\/MD.0000000000016682.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"3823_CR19","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1093\/rheumatology\/keaa904","volume":"60","author":"O Berardicurti","year":"2021","unstructured":"Berardicurti O, Conforti A, Iacono D, et al. Dissecting the clinical heterogeneity of adult-onset Still\u2019s disease: results from a multi-dimensional characterization and stratification. Rheumatol (Oxford). 2021;60(10):4844\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keaa904.","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"3823_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02688-4","volume":"23","author":"R Li","year":"2021","unstructured":"Li R, Liu X, Chen G, et al. Clinical phenotypes and prognostic factors of adult-onset Still\u2019s disease: data from a large inpatient cohort. Arthritis Res Ther. 2021;23(1):300. https:\/\/doi.org\/10.1186\/s13075-021-02688-4.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3823_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-018-0255-8","volume":"16","author":"G Ferrara","year":"2018","unstructured":"Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16(1):46. https:\/\/doi.org\/10.1186\/s12969-018-0255-8.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"3823_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2021","unstructured":"Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;74(4):553\u201369. https:\/\/doi.org\/10.1002\/art.42037.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"3823_CR23","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/rheumatology\/kead461","volume":"63","author":"HL Leavis","year":"2024","unstructured":"Leavis HL, van Daele PLA, Mulders-Manders C, et al. Management of adult-onset Still\u2019s disease: evidence- and consensus-based recommendations by experts. Rheumatol (Oxford). 2024;63(6):1656\u201363. https:\/\/doi.org\/10.1093\/rheumatology\/kead461.","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"3823_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/mr\/roaf058","volume":"36","author":"Y Hayashi","year":"2025","unstructured":"Hayashi Y, Mori M, Takase H, Shimizu M. Subcutaneous administration of methotrexate in children with paediatric rheumatic diseases. Mod Rheumatol. 2025;36(1):159\u201362. https:\/\/doi.org\/10.1093\/mr\/roaf058.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"3823_CR25","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1136\/ard-2024-225854","volume":"83","author":"S Bindoli","year":"2024","unstructured":"Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F. Efficacy and safety of therapies for Still\u2019s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR\/PReS guidelines for the management of Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1731\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3823_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/1740774518761367","volume":"15","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Beukelman T, Tomlinson G, Feldman BM, Schanberg LE, Kimura Y. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line options for systemic juvenile idiopathic arthritis treatment (FROST). Clin Trials. 2018;15(3):268\u201377. https:\/\/doi.org\/10.1177\/1740774518761367.","journal-title":"Clin Trials"},{"issue":"8","key":"3823_CR27","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3899\/jrheum.141567","volume":"42","author":"M Pardeo","year":"2015","unstructured":"Pardeo M, Pires Marafon D, Insalaco A, et al. Anakinra in systemic juvenile idiopathic arthritis: a single-center experience. J Rheumatol. 2015;42(8):1523\u20137. https:\/\/doi.org\/10.3899\/jrheum.141567.","journal-title":"J Rheumatol"},{"issue":"7","key":"3823_CR28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","volume":"13","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Jamilloux Y, Iwaz J, S\u00e8ve P. Adult-onset Still\u2019s disease. Autoimmun Rev. 2014;13(7):708\u201322. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.058.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"3823_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","volume":"14","author":"E Feist","year":"2018","unstructured":"Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease. Nat Rev Rheumatol. 2018;14(10):603\u201318. https:\/\/doi.org\/10.1038\/s41584-018-0081-x.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"3823_CR30","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1007\/s10067-024-07127-8","volume":"43","author":"K Daghor-Abbaci","year":"2024","unstructured":"Daghor-Abbaci K, Laraba N, Dahou-Makhloufi C, et al. Disease activity score for Still\u2019s disease. Clin Rheumatol. 2024;43(11):3273\u201383. https:\/\/doi.org\/10.1007\/s10067-024-07127-8.","journal-title":"Clin Rheumatol"},{"key":"3823_CR31","unstructured":"Ruscitti P, Stamm T, Ritschl V, et al. The development of the EULAR score for the definition of disease activity in adult-onset Still\u2019s disease. The \u201cDAVID\u201d Project. Abstract 2023. ACR Convergence. 2024"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03823-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:01:57Z","timestamp":1791752517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03823-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,11]]},"references-count":31,"alternative-id":["3823"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03823-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,11]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Karima Daghor-Abbaci has nothing to disclose. Oya Koker has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}